Somewhat Positive Press Coverage Somewhat Unlikely to Impact Charles River Laboratories International (NYSE:CRL) Stock Price

Headlines about Charles River Laboratories International (NYSE:CRL) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Charles River Laboratories International earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 47.9576736946966 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news stories that may have effected Accern’s scoring:

A number of equities research analysts recently issued reports on CRL shares. Barclays PLC set a $90.00 price target on Charles River Laboratories International and gave the stock a “hold” rating in a research note on Saturday, May 13th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 price target for the company in a research note on Thursday. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 20th. Jefferies Group LLC reissued a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, June 14th. Finally, Citigroup Inc. reissued a “neutral” rating and set a $104.00 price target (up from $90.00) on shares of Charles River Laboratories International in a research note on Thursday, May 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $96.94.

Shares of Charles River Laboratories International (NYSE CRL) opened at 97.97 on Friday. The company’s 50 day moving average price is $99.80 and its 200-day moving average price is $91.67. The company has a market capitalization of $4.66 billion, a price-to-earnings ratio of 25.82 and a beta of 1.02. Charles River Laboratories International has a 52 week low of $67.20 and a 52 week high of $102.32.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.07. The company had revenue of $469.13 million during the quarter, compared to analyst estimates of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The firm’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.20 earnings per share. Analysts anticipate that Charles River Laboratories International will post $5.10 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has authorized a stock repurchase program on Wednesday, May 10th that allows the company to repurchase $150.00 million in shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

In other news, Chairman James C. Foster sold 43,154 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total transaction of $4,315,400.00. Following the completion of the transaction, the chairman now directly owns 361,178 shares in the company, valued at $36,117,800. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman James C. Foster sold 9,516 shares of the firm’s stock in a transaction on Monday, July 10th. The stock was sold at an average price of $98.92, for a total value of $941,322.72. Following the transaction, the chairman now owns 361,171 shares of the company’s stock, valued at $35,727,035.32. The disclosure for this sale can be found here. Insiders sold 79,369 shares of company stock valued at $7,846,412 over the last quarter. 2.20% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.thestockobserver.com/2017/08/12/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-charles-river-laboratories-international-nysecrl-stock-price.html.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply